Skip to content
Journal article

2-aminothiazoles as therapeutic leads for prion diseases

Gallardo-Godoy A, Gever J, Fife K, Silber B, Prusiner S, Renslo A ...see all

Journal of Medicinal Chemistry, vol. 54, issue 4 (2011) pp. 1010-1021

  • 73

    Readers

    Mendeley users who have this article in their library.
  • 76

    Citations

    Citations of this article.
  • N/A

    Views

    ScienceDirect users who have downloaded this article.
Sign in to save reference

Abstract

2-Aminothiazoles are a new class of small molecules with antiprion activity in prion-infected neuroblastoma cell lines (J. Virol. 2010, 84, 3408). We report here structure-activity studies undertaken to improve the potency and physiochemical properties of 2-aminothiazoles, with a particular emphasis on achieving and sustaining high drug concentrations in the brain. The results of this effort include the generation of informative structure-activity relationships (SAR) and the identification of lead compounds that are orally absorbed and achieve high brain concentrations in animals. The new aminothiazole analogue (5-methylpyridin-2-yl)-[4-(3-phenylisoxazol-5-yl)-thiazol-2-yl]-amine (27), for example, exhibited an EC(50) of 0.94 μM in prion-infected neuroblastoma cells (ScN2a-cl3) and reached a concentration of ∼25 μM in the brains of mice following three days of oral administration in a rodent liquid diet. The studies described herein suggest 2-aminothiazoles as promising new leads in the search for effective therapeutics for prion diseases.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • Alejandra Gallardo-Godoy

  • Joel Gever

  • Kimberly L. Fife

  • B. Michael Silber

  • Stanley B. Prusiner

  • Adam R. Renslo

Cite this document

Choose a citation style from the tabs below